SpringerLink
Log in

MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy

  • Research Article
  • Published:
Tumor Biology

Abstract

This study aims to investigate the prognostic significance of the MYC protein expression in diffuse large B cell lymphoma (DLBCL) patients treated with RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). A total of 60 patients with DLBCL from 2008 to 2013 were included. Formalin-fixed, paraffin-embedded DLBCL samples were analyzed for MYC protein expression and divided into high or low MYC group. The MYC protein expression and the international prognostic variables were evaluated. The high MYC protein expression predicted a shorter 3-year estimated overall survival (OS) and progression-free survival (PFS) versus the low MYC protein expression (57 % vs. 96 %, P < 0.001 and 50 % vs. 96 %, P = 0.001, respectively). Multivariate analysis confirmed the prognostic significance of the MYC protein expression for both OS (HR, 11.862; 95 % CI, 1.462–96.218; P = 0.021) and PFS (HR, 6.073; 95 % CI, 1.082–34.085; P = 0.040). MYC protein expression with International Prognostic Index (IPI) score distinguished patients into three risk groups with different 3-year OS rates (χ 2 23.079; P < 0.001) and distinct 3-year PFS rates (χ 2 15.862; P < 0.001). This study suggests that the MYC protein expression is an important inferior prognostic factor for survival in patients with DLBCL treated with RCHOP. The combinative model with IPI score and MYC protein expression could stratify DLBCL patients into prognostically relevant subgroups more effectively than either the IPI or the MYC alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Reference

  1. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2012;2012:402–9.

    Google Scholar 

  2. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7.

    Article  CAS  PubMed  Google Scholar 

  3. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–5.

    Article  CAS  PubMed  Google Scholar 

  4. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.

    Article  CAS  PubMed  Google Scholar 

  5. Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216(4):440–50.

    Article  CAS  PubMed  Google Scholar 

  6. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of cmyc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol. 2010;34(6):882–91.

    Article  PubMed  Google Scholar 

  8. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7(4):e33813.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Tapia G, Lopez R, Muñoz-Mármol AM, Mate JL, Sanz C, Marginet R, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59(4):672–8.

    Article  PubMed  Google Scholar 

  10. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

    Article  CAS  PubMed  Google Scholar 

  11. National Comprehensive Cancer Network Inc. NCCN Non-Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology. NCCN Web site. 2013.

  12. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94.

  13. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63.

    Article  CAS  PubMed  Google Scholar 

  14. Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood. 2012;120(22):4400–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7.

    Article  CAS  PubMed  Google Scholar 

  16. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Aref S, Mabed M, Zalata K, Sakrana M, El Askalany H. The interplay between cMyc oncogene expression and circulating vascular endothelial growth factor(sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome. Leuk Lymphoma. 2004;45:499–506.

    Article  CAS  PubMed  Google Scholar 

  19. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37(4):382–90.

    Article  CAS  PubMed  Google Scholar 

  20. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173–83.

    Article  CAS  PubMed  Google Scholar 

  21. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-Kb in lymphoid malignancies. Immunol Rev. 2012;246(1):359–78.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.

    Article  CAS  PubMed  Google Scholar 

  23. Sengar M, Menon H, Dangi H, Bagal B, Khattry N. Comparison of treatment outcomes with EPOCH-Rituximab versus CHOP-rituximab in patients with de-novo intermediate and high risk international prognostic index (IPI) diffuse large B cell lymphoma (DLBCL): a single center retrospective analysis. Blood. 2013;122:e5115.

    Google Scholar 

Download references

Acknowledgments

This work was founded by Nan**g Major Program for Medical Science and Technology, the Key Project Supported by Medical Science and Technology Development Foundation of Nan**g Department of Health (No. ZKX09016), and Jiangsu Provincial Special Program of Medical Science (No.BL2012005).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Hematology, Nan**g Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nan**g University of Chinese Medicine, Nan**g, 210008, People’s Republic of China

    Min Zhou, **g Wang, Jian Ouyang, **g-yan Xu, Bing Chen, Qi-guo Zhang, Rong-fu Zhou, Yong-gong Yang, **ao-yan Shao, Yong Xu & Ya-mei Chen

  2. Department of Pathology, The Affiliated Drum Tower Hospital of Nan**g University Medical School, Nan**g, 210008, People’s Republic of China

    **ang-shan Fan & Hong-yan Wu

Authors
  1. Min Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **g Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. **g-yan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qi-guo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rong-fu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-gong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. **ao-yan Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ya-mei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. **ang-shan Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hong-yan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Ouyang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, M., Wang, J., Ouyang, J. et al. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. Tumor Biol. 35, 6757–6762 (2014). https://doi.org/10.1007/s13277-014-1907-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1907-z

Keywords

Search

Navigation